Cargando…

Comparing Predictions of a PBPK Model for Cyclosporine With Drug Levels From Therapeutic Drug Monitoring

This study compared simulations of a physiologically based pharmacokinetic (PBPK) model implemented for cyclosporine with drug levels from therapeutic drug monitoring to evaluate the predictive performance of a PBPK model in a clinical population. Based on a literature search model parameters were d...

Descripción completa

Detalles Bibliográficos
Autores principales: Zapke, Sonja E., Willmann, Stefan, Grebe, Scott-Oliver, Menke, Kristin, Thürmann, Petra A., Schmiedl, Sven
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8161189/
https://www.ncbi.nlm.nih.gov/pubmed/34054518
http://dx.doi.org/10.3389/fphar.2021.630904
_version_ 1783700451436265472
author Zapke, Sonja E.
Willmann, Stefan
Grebe, Scott-Oliver
Menke, Kristin
Thürmann, Petra A.
Schmiedl, Sven
author_facet Zapke, Sonja E.
Willmann, Stefan
Grebe, Scott-Oliver
Menke, Kristin
Thürmann, Petra A.
Schmiedl, Sven
author_sort Zapke, Sonja E.
collection PubMed
description This study compared simulations of a physiologically based pharmacokinetic (PBPK) model implemented for cyclosporine with drug levels from therapeutic drug monitoring to evaluate the predictive performance of a PBPK model in a clinical population. Based on a literature search model parameters were determined. After calibrating the model using the pharmacokinetic profiles of healthy volunteers, 356 cyclosporine trough levels of 32 renal transplant outpatients were predicted based on their biometric parameters. Model performance was assessed by calculating absolute and relative deviations of predicted and observed trough levels. The median absolute deviation was 6 ng/ml (interquartile range: 30 to 31 ng/ml, minimum = −379 ng/ml, maximum = 139 ng/ml). 86% of predicted cyclosporine trough levels deviated less than twofold from observed values. The high intra-individual variability of observed cyclosporine levels was not fully covered by the PBPK model. Perspectively, consideration of clinical and additional patient-related factors may improve the model’s performance. In summary, the current study has shown that PBPK modeling may offer valuable contributions for pharmacokinetic research in clinical drug therapy.
format Online
Article
Text
id pubmed-8161189
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher Frontiers Media S.A.
record_format MEDLINE/PubMed
spelling pubmed-81611892021-05-29 Comparing Predictions of a PBPK Model for Cyclosporine With Drug Levels From Therapeutic Drug Monitoring Zapke, Sonja E. Willmann, Stefan Grebe, Scott-Oliver Menke, Kristin Thürmann, Petra A. Schmiedl, Sven Front Pharmacol Pharmacology This study compared simulations of a physiologically based pharmacokinetic (PBPK) model implemented for cyclosporine with drug levels from therapeutic drug monitoring to evaluate the predictive performance of a PBPK model in a clinical population. Based on a literature search model parameters were determined. After calibrating the model using the pharmacokinetic profiles of healthy volunteers, 356 cyclosporine trough levels of 32 renal transplant outpatients were predicted based on their biometric parameters. Model performance was assessed by calculating absolute and relative deviations of predicted and observed trough levels. The median absolute deviation was 6 ng/ml (interquartile range: 30 to 31 ng/ml, minimum = −379 ng/ml, maximum = 139 ng/ml). 86% of predicted cyclosporine trough levels deviated less than twofold from observed values. The high intra-individual variability of observed cyclosporine levels was not fully covered by the PBPK model. Perspectively, consideration of clinical and additional patient-related factors may improve the model’s performance. In summary, the current study has shown that PBPK modeling may offer valuable contributions for pharmacokinetic research in clinical drug therapy. Frontiers Media S.A. 2021-05-14 /pmc/articles/PMC8161189/ /pubmed/34054518 http://dx.doi.org/10.3389/fphar.2021.630904 Text en Copyright © 2021 Zapke, Willmann, Grebe, Menke, Thürmann and Schmiedl. https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
spellingShingle Pharmacology
Zapke, Sonja E.
Willmann, Stefan
Grebe, Scott-Oliver
Menke, Kristin
Thürmann, Petra A.
Schmiedl, Sven
Comparing Predictions of a PBPK Model for Cyclosporine With Drug Levels From Therapeutic Drug Monitoring
title Comparing Predictions of a PBPK Model for Cyclosporine With Drug Levels From Therapeutic Drug Monitoring
title_full Comparing Predictions of a PBPK Model for Cyclosporine With Drug Levels From Therapeutic Drug Monitoring
title_fullStr Comparing Predictions of a PBPK Model for Cyclosporine With Drug Levels From Therapeutic Drug Monitoring
title_full_unstemmed Comparing Predictions of a PBPK Model for Cyclosporine With Drug Levels From Therapeutic Drug Monitoring
title_short Comparing Predictions of a PBPK Model for Cyclosporine With Drug Levels From Therapeutic Drug Monitoring
title_sort comparing predictions of a pbpk model for cyclosporine with drug levels from therapeutic drug monitoring
topic Pharmacology
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8161189/
https://www.ncbi.nlm.nih.gov/pubmed/34054518
http://dx.doi.org/10.3389/fphar.2021.630904
work_keys_str_mv AT zapkesonjae comparingpredictionsofapbpkmodelforcyclosporinewithdruglevelsfromtherapeuticdrugmonitoring
AT willmannstefan comparingpredictionsofapbpkmodelforcyclosporinewithdruglevelsfromtherapeuticdrugmonitoring
AT grebescottoliver comparingpredictionsofapbpkmodelforcyclosporinewithdruglevelsfromtherapeuticdrugmonitoring
AT menkekristin comparingpredictionsofapbpkmodelforcyclosporinewithdruglevelsfromtherapeuticdrugmonitoring
AT thurmannpetraa comparingpredictionsofapbpkmodelforcyclosporinewithdruglevelsfromtherapeuticdrugmonitoring
AT schmiedlsven comparingpredictionsofapbpkmodelforcyclosporinewithdruglevelsfromtherapeuticdrugmonitoring